-

One A Day® Launches Science-Backed Cellular Aging Support Supplement

  • New One A Day® Age Factor™ Cell Defense supplement helps defend against cellular aging from the inside out
  • Age Factor™ portfolio includes free wellness app to get insights on current habits and how to make incremental lifestyle changes to support a healthy aging journey

WHIPPANY, N.J.--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand rooted in 80+ years of nutritional science, announced today the launch of One A Day® Age Factor™ Cell Defense, a dietary supplement that helps defend against cellular aging from the inside – where aging begins.

One A Day® Age Factor™ Cell Defense supports cell health and resilience throughout the aging journey, as cells naturally become less effective at managing everyday stressors. Cellular or biological age – how old a person’s cells are – may not always match one’s chronological age, with genetics (about 20%) and lifestyle factors serving as core contributors to the cellular aging process. One A Day® Age Factor™ Cell Defense is specially designed with olive polyphenols, an antioxidant derived from olive fruit extract that helps defend against the damaging effects of daily stressors. Age Factor™ also includes Omega-3 fatty acids, Resveratrol, Astaxanthin, Vitamin C, Vitamin D, and Niacin to help support cell resilience throughout aging.

“Healthy aging has increasingly become a priority for consumers. Bayer is excited to offer them a new, scientifically designed supplement to proactively support their cell health as they age,” said Lisa Perez, General Manager and VP Marketing, Nutritionals at Bayer. “The anti-aging space is overwhelming, with lots of information that can make it challenging for consumers to feel confident about the choices they are making. One A Day wants to help consumers cut through the noise and is committed to creating products backed by science and in this case, one that targets cellular aging from the inside – where aging begins.”

Designed to provide holistic support for a healthy aging journey, the Age Factor™ portfolio includes a supplement and a free wellness app to get valuable insights on current habits and how to make incremental lifestyle changes to support a healthy aging journey. The One A Day® Age Factor™ Cell Defense dietary supplement is available for purchase online and at mass retail locations. Consumers can download the wellness app from the Google or Apple App store.

Earlier this year, Bayer launched the Bayer Precision Health group, a business unit focused on developing new precision consumer health products. The launch of the One A Day® Age Factor™ Cell Defense line is the latest innovation, and underlines Bayer’s commitment to empower consumers to take smarter health choices on their aging journey. For more information on One A Day® please visit oneaday.com or follow us on Instagram and X.

About One A Day

One A Day is a multivitamin and supplement brand offering specially formulated products for many members of the family. From prenatal to 65+, One A Day offers complete multivitamins for different ages, genders, and health goals. The portfolio includes tablet, soft gel, and gummy products. One A Day products are available at most major drugstores and retailers nationwide.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Contacts

Jan Schlegelmilch
Director, Integrated Communications, Bayer Consumer Health U.S.
jan.schlegelmilch@bayer.com

Halle Foster
Account Supervisor, Media & Engagement, twelvenote agency
hfoster@twelvenote.com

Bayer


Release Versions

Contacts

Jan Schlegelmilch
Director, Integrated Communications, Bayer Consumer Health U.S.
jan.schlegelmilch@bayer.com

Halle Foster
Account Supervisor, Media & Engagement, twelvenote agency
hfoster@twelvenote.com

More News From Bayer

Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road

WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the road at a critical moment: a Harris Poll survey of 2,023 US adults, commissioned by Bayer – Science Under Siege: The Battle Between Viral Misinformation and Shared Belief in the Value of Science (March 2026) – found that 82% worry about their own and their families' wellbeing due...

U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer

WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC...

BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the initiation of a global Phase II clinical trial (NCT07625215) evaluating BAY 3670549, an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor, which has the potential as a new approach to control the electrical activity of heart cells in patients with atrial fibrillation (AFib). The Phase II single-treatment study in a randomized, double-blind, placebo-controlled, parallel-group, mu...
Back to Newsroom